AR054139A1 - Formulacion modificada y de liberacion inmediata de esferas de memantina - Google Patents
Formulacion modificada y de liberacion inmediata de esferas de memantinaInfo
- Publication number
- AR054139A1 AR054139A1 ARP060102596A ARP060102596A AR054139A1 AR 054139 A1 AR054139 A1 AR 054139A1 AR P060102596 A ARP060102596 A AR P060102596A AR P060102596 A ARP060102596 A AR P060102596A AR 054139 A1 AR054139 A1 AR 054139A1
- Authority
- AR
- Argentina
- Prior art keywords
- immediate release
- memantine
- spheres
- modified
- modified formation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Formas de dosificacion oral de liberacion inmediata y liberacion modificada. Específicamente, formas farmacéuticas de liberacion modificada e inmediata que contienen memantina, que presentan un perfil de liberacion mejorada y proporcionan una absorcion confiable. Las formas de dosificacion pueden usarse para tratar la enfermedad de Alzheimer leve, moderada o severa, o el dolor neuropático.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69151205P | 2005-06-16 | 2005-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054139A1 true AR054139A1 (es) | 2007-06-06 |
Family
ID=37025104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102596A AR054139A1 (es) | 2005-06-16 | 2006-06-16 | Formulacion modificada y de liberacion inmediata de esferas de memantina |
Country Status (10)
Country | Link |
---|---|
US (6) | US20070065512A1 (es) |
EP (1) | EP1898890A1 (es) |
JP (1) | JP2008543845A (es) |
AR (1) | AR054139A1 (es) |
AU (1) | AU2006259619A1 (es) |
CA (1) | CA2607600A1 (es) |
EA (1) | EA013474B1 (es) |
TW (1) | TW200716208A (es) |
WO (1) | WO2006138227A1 (es) |
ZA (1) | ZA200710270B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
AU2005265031A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
MX2007006120A (es) * | 2004-11-23 | 2007-12-07 | Adamas Pharmaceuticals Inc | Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda. |
MX2007012374A (es) | 2005-04-06 | 2008-02-22 | Adamas Pharmaceuticals Inc | Metodos y composiciones para el tratamiento de condiciones relacionadas con cns. |
US20070092577A1 (en) * | 2005-10-03 | 2007-04-26 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
US20080008752A1 (en) * | 2006-07-05 | 2008-01-10 | Julia Hrakovsky | Pharmaceutical compositions of memantine |
US20080008743A1 (en) * | 2006-07-06 | 2008-01-10 | Forest Laboratories Holdings Limited | Orally Dissolving Formulations of Memantine |
GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
US20080182908A1 (en) * | 2007-01-25 | 2008-07-31 | Vinita Umashankar Vyas | Pharmaceutical compositions comprising memantine |
CN101742998B (zh) | 2007-03-22 | 2014-09-17 | 玛格塞蒂克斯公司 | 镁组合物及其用途 |
FR2936709B1 (fr) * | 2008-10-02 | 2012-05-11 | Ethypharm Sa | Comprimes alcoolo-resistants. |
WO2010112221A1 (en) | 2009-04-03 | 2010-10-07 | Synthon B.V. | Pharmaceutical compositions comprising memantine |
CN102781259A (zh) | 2009-09-30 | 2012-11-14 | 加利福尼亚大学董事会 | 辅因子及个体使用方法 |
JP2013529604A (ja) * | 2010-06-24 | 2013-07-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ネラメキサン複数単位剤形 |
US8501816B2 (en) | 2010-10-12 | 2013-08-06 | Cerecor, Inc. | Antitussive compositions comprising memantine |
CN102552218A (zh) * | 2010-12-31 | 2012-07-11 | 无锡万全医药技术有限公司 | 一种盐酸美金刚胶囊缓释剂及其制备方法 |
US20140004189A1 (en) * | 2011-01-25 | 2014-01-02 | Cadila Healthcare Limited | Modified release pharmaceutical compositions memantine |
WO2012110912A1 (en) * | 2011-02-17 | 2012-08-23 | Lupin Limited | Sustained release composition of memantine |
TR201104108A2 (tr) | 2011-04-27 | 2011-08-22 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salımlı memantin tablet. |
US8617886B2 (en) | 2011-07-15 | 2013-12-31 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
CN103181914B (zh) * | 2011-12-27 | 2014-11-05 | 上海复星医药产业发展有限公司 | 盐酸美金刚缓释胶囊及其制备方法 |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US20130274342A1 (en) * | 2012-04-12 | 2013-10-17 | Cerecor, Inc. | Compositions and methods for treating cough |
ES2623176T3 (es) | 2012-08-16 | 2017-07-10 | Teva Pharmaceutical Industries Ltd. | Composición farmacéutica de memantina |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
EP2945616B1 (en) | 2013-01-15 | 2018-11-28 | NuSirt Sciences, Inc. | Treating pulmonary conditions |
US9585876B2 (en) | 2013-03-15 | 2017-03-07 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
CN106456997B (zh) | 2014-02-27 | 2018-12-28 | 纽斯尔特科学公司 | 用于减少或预防肝性脂肪变性的组合物和方法 |
CN104013592B (zh) * | 2014-06-10 | 2017-12-15 | 浙江京新药业股份有限公司 | 盐酸美金刚缓释药丸及其制备方法 |
US10350165B2 (en) | 2014-12-12 | 2019-07-16 | Ojai Energetics Pbc | Methods and systems for forming stable droplets |
JP2018505912A (ja) | 2014-12-12 | 2018-03-01 | オーハイ エナジェティクス ピービーシー | マイクロカプセル化カンナビノイド組成物 |
EP3395330B1 (en) * | 2015-12-23 | 2019-10-23 | Laboratorios Bagó S.A. | Premixture and pharmaceutical composition for the oral administration of memantine as a permanent suspension or prepared prior to administration to the patient, optionally via an enteral feeding tube, and corresponding methods |
JP6420508B2 (ja) * | 2017-02-10 | 2018-11-07 | 大原薬品工業株式会社 | 化学的な安定性が改善された、メマンチン塩酸塩を含有する製剤 |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
EP3624779B1 (en) * | 2017-05-19 | 2024-04-03 | Biscayne Neurotherapeutics, Inc. | Modified release pharmaceutical compositions of huperzine and methods of using the same |
JP6990719B2 (ja) * | 2017-06-14 | 2022-01-12 | スペックジーエックス エルエルシー | 遅延持続放出医薬組成物 |
CN108969506A (zh) * | 2018-09-11 | 2018-12-11 | 山东鲁抗医药股份有限公司 | 一种盐酸美金刚缓释微丸及其制备方法 |
WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
CN109172538A (zh) * | 2018-10-25 | 2019-01-11 | 安徽鼎旺医药有限公司 | 一种盐酸美金刚速溶微丸软胶囊 |
WO2020131921A1 (en) | 2018-12-18 | 2020-06-25 | Ojai Energetics Pbc | Cannabinoid compositions for virtual and augmented reality experiences |
CN113546063A (zh) * | 2020-04-26 | 2021-10-26 | 江苏天士力帝益药业有限公司 | 一种盐酸美金刚缓释胶囊及其制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7305644A (es) * | 1972-04-20 | 1973-10-23 | ||
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
DE58905637D1 (de) * | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
PL193237B1 (pl) * | 1997-06-30 | 2007-01-31 | Merz Pharma Gmbh & Co Kgaa | Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie |
US6413556B1 (en) * | 1999-01-08 | 2002-07-02 | Sky High, Llc | Aqueous anti-apoptotic compositions |
SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US7135465B2 (en) * | 2000-03-30 | 2006-11-14 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
AU2002229056A1 (en) * | 2000-12-07 | 2002-06-18 | Neuromolecular Inc. | Methods for treating neuropsychiatric disorders with NMDA receptor antagonists |
US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
WO2005072705A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
AU2005265031A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
-
2006
- 2006-06-12 WO PCT/US2006/022841 patent/WO2006138227A1/en active Application Filing
- 2006-06-12 CA CA002607600A patent/CA2607600A1/en not_active Abandoned
- 2006-06-12 JP JP2008516983A patent/JP2008543845A/ja active Pending
- 2006-06-12 EP EP06772944A patent/EP1898890A1/en not_active Withdrawn
- 2006-06-12 AU AU2006259619A patent/AU2006259619A1/en not_active Abandoned
- 2006-06-12 EA EA200800064A patent/EA013474B1/ru not_active IP Right Cessation
- 2006-06-14 TW TW095121264A patent/TW200716208A/zh unknown
- 2006-06-14 US US11/424,024 patent/US20070065512A1/en not_active Abandoned
- 2006-06-16 AR ARP060102596A patent/AR054139A1/es not_active Application Discontinuation
-
2007
- 2007-11-28 ZA ZA200710270A patent/ZA200710270B/xx unknown
-
2012
- 2012-02-15 US US13/396,776 patent/US20120201889A1/en not_active Abandoned
- 2012-09-14 US US13/617,870 patent/US20130011474A1/en not_active Abandoned
-
2013
- 2013-07-17 US US13/944,434 patent/US20130302430A1/en not_active Abandoned
-
2015
- 2015-05-27 US US14/722,589 patent/US20150258042A1/en not_active Abandoned
-
2016
- 2016-08-11 US US15/234,870 patent/US20160346227A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006259619A1 (en) | 2006-12-28 |
EP1898890A1 (en) | 2008-03-19 |
US20130302430A1 (en) | 2013-11-14 |
EA200800064A1 (ru) | 2008-04-28 |
CA2607600A1 (en) | 2006-12-28 |
US20150258042A1 (en) | 2015-09-17 |
EA013474B1 (ru) | 2010-04-30 |
WO2006138227A1 (en) | 2006-12-28 |
TW200716208A (en) | 2007-05-01 |
JP2008543845A (ja) | 2008-12-04 |
US20130011474A1 (en) | 2013-01-10 |
US20160346227A1 (en) | 2016-12-01 |
ZA200710270B (en) | 2008-12-31 |
US20070065512A1 (en) | 2007-03-22 |
US20120201889A1 (en) | 2012-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054139A1 (es) | Formulacion modificada y de liberacion inmediata de esferas de memantina | |
CL2017000669A1 (es) | Forma de dosificación farmacéutica (divisional de la solicitud 1029/2014) | |
CR9848A (es) | Combinacion de rosiglitazona y donepezil para mejorar la funcion cognitiva | |
HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
BRPI0607017B8 (pt) | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc | |
ECSP045429A (es) | Combinacion de compuestos organicos | |
AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
CY1112738T1 (el) | Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη | |
AR109263A2 (es) | Composición que comprende moxidectina | |
PE20070333A1 (es) | Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos | |
BRPI0519198A2 (pt) | moduladores de delta-opiàide tricÍclicos | |
CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
CL2004001365A1 (es) | Compuestos derivados de 3-fluoropiperidina; composicion farmaceutica que lo comprende; y uso del compuesto para tratar o prevenir el dolor o la enfermedad de parkinson. | |
CR10524A (es) | Compuesto triciclico y uso farmaceutico del mismo | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
AR070392A1 (es) | Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion | |
CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
PA8571901A1 (es) | Nueva composicion farmaceutica | |
CL2008001477A1 (es) | Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico | |
CL2011000387A1 (es) | Combinacion que comprende a) 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol y b) paracetamol; forma de dosificacion; uso para tratar osteoartritis y dolor. | |
GT200500032A (es) | Piperazinas derivadas de urea para el tratamiento de la endometrosis | |
AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |